Nucala 100 MG/ML auto-injectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FCRQ1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,591
Award facts
- Contract value 100% obligated
- $11,591.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $11,591.04 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Nucala 100 mg/mL auto-injector units. This firm fixed-price delivery order, awarded on December 15, 2025, with an ultimate completion date of December 16, 2025, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion contract awarded on November 13, 2025, that positions the company as a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, specializing in distributing a comprehensive range of pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide. The PPV-G GEN V contract, structured with a 30-month base period and three 30-month option periods extending through December 31, 2036, authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for branded and generic prescription drugs, biologics, and medical consumables to support recurring military healthcare needs. The contractor's demonstrated performance across numerous delivery orders spanning multiple therapeutic categories, including specialty biologics such as Nucala, reflects its capability to fulfill the diverse and specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FCRQ1?
SPE2DR26FCRQ1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 15, 2025.
How much is contract SPE2DR26FCRQ1 worth?
The government has obligated $11,591 on SPE2DR26FCRQ1.
Is contract SPE2DR26FCRQ1 an order under another contract?
Yes. SPE2DR26FCRQ1 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRQ1 competed?
The extent of competition for SPE2DR26FCRQ1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award